Author/Authors :
Nafar Mohsen نويسنده , Nemati Eghlim نويسنده , Mahdavi-Mazdeh Mitra نويسنده , Rashid-Farokhi Farin نويسنده , Argani Hassan نويسنده , Zeraati Abbas Ali نويسنده Iran3Department of Nephrology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad , Sagheb Mohammad Mahdi نويسنده Section of Nephrology, Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. , Afshar Reza نويسنده Department of Internal Medicine, School of Medicine, Shahed University, Tehran , Ossareh Shahrzad نويسنده Hasheminejad Kidney Center,Iran University of Medical Science,Tehran,Iran , Atapour Abdolah نويسنده Isfahan Kidney Disease Research Center (IKRC), Isfahan, Iran , Poor Reza Gholi Fatemeh نويسنده Department of Nephrology, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , Hakemi Monir Sadat نويسنده Depatment of Nephrology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran , Tara Seied Ahmad نويسنده Department of Nephrology, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran , Reza Ahmadi Javad Mohamd نويسنده Shahid Beheshti University of Medical Sciences, Tehran, Iran , Karimi Nadia نويسنده Shahid Beheshti University of Medical Sciences, Tehran, Iran , Mamdouhi Fereshteh نويسنده Kidney Transplantation Complications Research Center, Mashhad University of Medical Sciences, Mashhad, Iran , Sabaghian Tahereh نويسنده Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
[Background]The aim of this study was to evaluate the management of mineral and bone disorders (MBD) in patients with chronic kidney disease (CKD) in Iran and the extent to which KDIGO goals were met.[Methods]This multi-centre observational study was conducted on patients with CKD stages 4, 5, and 5D. Data were collected from a total of 209 patients with no surgical or medical conditions that precluded their participation. This study assessed the frequency of measurements, serum levels of phosphorus (P), calcium (Ca), and parathyroid hormone (PTH), the achievement of the targets recommended by the 2009 KDIGO guidelines, and the presence of vascular/valvular calcification.[Results]The KDIGO targets for P, Ca, and iPTH, were achieved in 47%, 51%, and 18% of the patients with stage 4 + 5 and in 63%, 50%, and 44% of the patients with stage 5D, respectively. The serum PTH level of 18% of the patients with CKD stage 4 + 5 was within the recommended range, while it was higher than the recommended level in other patients. Among patients with CKD stage 5D, the serum PTH level was within, below, and above the recommended range in 44%, 39%, and 17% of the patients, respectively. The frequency of the measurement of the blood levels of Ca, P, and PTH were based on the 2009 KDIGO guidelines in 88% of patients. Forty-six percent of cases were screened for vascular/valvular calcification, 30% of whom had calcification at least in one site.[Conclusions]The current status is far from the targets recommended by the current guidelines in the management of CKD-MBD.
